The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma

This phase 2 study evaluated the activity and safety of ibrutinib, a Bruton’s tyrosine kinase inhibitor, plus rituximab in adults with previously untreated follicular lymphoma. Patients received once‐daily ibrutinib 560 mg continuously plus once‐weekly rituximab 375 mg/m(2) for 4 weeks beginning Wee...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Haematol
Asıl Yazarlar: Fowler, Nathan H., Nastoupil, Loretta, De Vos, Sven, Knapp, Mark, Flinn, Ian W., Chen, Robert, Advani, Ranjana H., Bhatia, Sumeet, Martin, Peter, Mena, Raul, Davis, Richard Eric, Neelapu, Sattva S., Eckert, Karl, Ping, Jerry, Co, Melannie, Beaupre, Darrin M., Neuenburg, Jutta K., Palomba, M. Lia
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2020
Konular:
Haematological Malignancy ‐ Clinical
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7317728/
https://ncbi.nlm.nih.gov/pubmed/32180219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16424
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller